H.R. 5313 — Drug Competition Act of 2000

Summary

Drug Competition Act of 2000 - Requires brand name drug manufacturers and generic drug manufacturers to notify the Federal Trade Commission and the Attorney General of agreements regarding the sale or manufacture of generic drugs which could have the effect of limiting the research, development, manufacture, marketing, or selling of a generic drug product.

Full Text

Legislative Actions

2000-09-27
Introduced in House
2000-09-27
Introduced in House
2000-09-27
Referred to the Committee on Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2000-09-27
Referred to the Committee on Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2000-09-27
Referred to the Committee on Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2000-10-20
Referred to the Subcommittee on Health and Environment.

Drug Competition Act of 2000

Sponsors

Subjects

Summary

Full Text

Legislative Actions

Ask about this bill